



THE AGA KHAN UNIVERSITY

eCommons@AKU

---

Department of Pathology and Laboratory  
Medicine

Medical College, Pakistan

---

10-1-2014

## Leishmania donovani bodies in bone marrow

Natasha Ali

*Aga Khan University*, [natasha.ali@aku.edu](mailto:natasha.ali@aku.edu)

Shabneez Hussain

*Aga Khan University*, [shabneez.hussain@aku.edu](mailto:shabneez.hussain@aku.edu)

Follow this and additional works at: [https://ecommons.aku.edu/pakistan\\_fhs\\_mc\\_pathol\\_microbiol](https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol)



Part of the [Hematology Commons](#), [Microbiology Commons](#), [Oncology Commons](#), and the [Pathology Commons](#)

---

### Recommended Citation

Ali, N., Hussain, S. (2014). Leishmania donovani bodies in bone marrow. *Clinical Case Reports*, 2(5), 238-239.

Available at: [https://ecommons.aku.edu/pakistan\\_fhs\\_mc\\_pathol\\_microbiol/891](https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/891)

## CLINICAL IMAGE

### ***Leishmania donovani* bodies in bone marrow**

Natasha Ali<sup>1</sup> & Shabneez Hussain<sup>2</sup>

<sup>1</sup>Section of Hematology, Department of Pathology and Microbiology/Oncology, The Aga Khan University Hospital, Karachi, Pakistan

<sup>2</sup>Section of Hematology, Department of Pathology and Microbiology, The Aga Khan University Hospital, Karachi, Pakistan

#### Correspondence

Shabneez Hussain, Section of Hematology, Department of Pathology and Microbiology, The Aga Khan University and Hospital, stadium road, Karachi, P.O. Box 3500, Pakistan, 74800. Tel: 00-92-213-4864511; Fax: 9221-34934294; E-mail: shabneez.malik@aku.edu

#### Funding Information

No funding provided.

Received: 3 March 2014; Revised: 26 April 2014; Accepted: 1 June 2014

*Clinical Case Reports* 2014; 2(5): 238–239

doi: 10.1002/ccr3.97

#### Dear Editor,

We report a case of a 5-year-old female, resident of Afghanistan who was evaluated for high grade, intermittent fevers over the last 5 months. On examination, she had pallor and massive splenomegaly. Complete blood count results showed hemoglobin: 7.6 g/dL, white blood cell count:  $2.3 \times 10^9/L$ , and platelet count:  $70 \times 10^9/L$ . The peripheral blood smear revealed anisocytosis, polychromasia and pancytopenia. Subsequently, bone marrow procedure was performed as a part of workup for evalua-

#### Key Clinical Message


We report a case of a 5-year-old female, resident of Afghanistan, who presented with fever and massive splenomegaly. Bone marrow revealed *Leishmania donovani* bodies (LD bodies) in macrophages characterized by a kinetoplast and characteristic double dot appearance. She was diagnosed as visceral leishmaniasis which is transmitted by sandflies (*Phlebotomus*).

#### Keywords

*Leishmania donovani* bodies, *Phlebotomus*, sandflies, visceral leishmaniasis.

tion of fever and splenomegaly. Bone marrow aspirate showed *Leishmania donovani* bodies (LD bodies) in macrophages characterized by a kinetoplast and characteristic double dot appearance (Fig. 1A and B). Normal hematopoiesis was noted. A diagnosis visceral leishmaniasis was made.

Leishmaniasis is caused by a protozoan, *Leishmania*, of which more than 20 species have been identified. *Leishmania* is transmitted by sandflies (*Phlebotomus*). It has an estimated annual incidence of 2 million cases in 98 countries [1] It manifests itself as three main clinical



**Figure 1.** (A and B) macrophage infested with intracellular *Leishmania donovani* bodies (arrows) characterized by a kinetoplast and characteristic double dot appearance (Leishman stain) (100× magnification).

syndromes: cutaneous, mucocutaneous, and visceral disease. Visceral leishmaniasis (kala-azar) occurs due to infestation of the macrophages in the reticuloendothelial system resulting in hepatosplenomegaly, while involvement of bone marrow leads to suppression of hemopoiesis. In countries like India, Pakistan, and China, visceral Leishmaniasis is caused by *Leishmania donovani*. In the Mediterranean region, *Leishmania infantum* is the culprit and *Leishmania tropica* is reported to be the causative agent in the Middle East [2]. Management includes amphotericin B, sodium stibogluconate or miltefosine [3–5].

## Conflict of Interest

None declared.

## References

1. World Health Organisation. 2010. Control of the leishmaniases. World Health Organ Tech Rep Ser:xii-xiii, 1-186, back cover
2. From the Centers for Disease Control. 1992. Viscerotropic leishmaniasis in persons returning from Operation Desert Storm – 1990–1991. *JAMA* 267:1444–1446.
3. Baiocco, P., G. Colotti, S. Franceschini, and A. Ilari. 2009. Molecular basis of antimony treatment in leishmaniasis. *J. Med. Chem.* 52:2603–2612.
4. Barratt, G., and P. Legrand. 2005. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. *Curr. Opin. Infect. Dis.* 18:527–530.
5. Jha, T. K., S. Sundar, C. P. Thakur, P. Bachmann, J. Karbwang, C. Fischer, et al. 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. *N. Engl. J. Med.* 341:1795–1800.